NCT01687257View on ClinicalTrials.gov

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

October 31, 2015

Conditions
Hepatitis CCirrhosisPortal HypertensionWith or Without Liver Decompensation
Interventions
DRUG

SOF

SOF 400 mg tablet administered orally once daily

DRUG

RBV

RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (9)

Unknown

Aurora

Boston

Rochester

Philadelphia

Newtown

Leclerc

Grafton

Barcelona

Majadahonda

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT01687257 - Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation | Biotech Hunter | Biotech Hunter